Ngā hua rapu - Mark D. Matteucci

  • E whakaatu ana i te 1 - 13 hua o te 13
Whakamahine hua
  1. 1
    Hybridization triggered cross-linking of deoxyoligonucleotides

    Hybridization triggered cross-linking of deoxyoligonucleotides mā Thomas R. Webb, Mark D. Matteucci

    I whakaputaina 1986
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Dialkylformamldines: depurination resistant N<sup>6</sup>-protecting group for deoxyadenosine

    Dialkylformamldines: depurination resistant N<sup>6</sup>-protecting group for deoxyadenosine mā Brian C. Froehler, Mark D. Matteucci

    I whakaputaina 1983
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Targeted random mutagenesis: the use of ambiguously synthesized oligonucleotides to mutagenize sequences immediately 5‘ of an ATG initiation codon

    Targeted random mutagenesis: the use of ambiguously synthesized oligonucleotides to mutagenize sequences immediately 5‘ of an ATG initiation codon mā Mark D. Matteucci, Herbert L. Heyneker

    I whakaputaina 1983
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Synthesis of DNA via deoxynudeoside H-phosphonate Intermediates

    Synthesis of DNA via deoxynudeoside H-phosphonate Intermediates mā Brian C. Froehler, Peter G. Ng, Mark D. Matteucci

    I whakaputaina 1986
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Triple helix formation inhibits transcription elongation in vitro.

    Triple helix formation inhibits transcription elongation in vitro. mā Stuart Young, S. H. KRAWCZYK, Mark D. Matteucci, J J Toole

    I whakaputaina 1991
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    An anti-parallel triple helix motif with oligodeoxynucleotidescontaining 2'-deoxyguanosine and 7-deaza-2'-deoxy xanthosine

    An anti-parallel triple helix motif with oligodeoxynucleotidescontaining 2'-deoxyguanosine and 7-deaza-2'-deoxy xanthosine mā John F. Milligan, Stevan H. Krawazyk, Shalini Wadwani, Mark D. Matteucci

    I whakaputaina 1993
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Oligonucleotide-mediated triple helix formation using an N3-protonated deoxycytidine analog exhibiting pH-independent binding within the physiological range.

    Oligonucleotide-mediated triple helix formation using an N3-protonated deoxycytidine analog exhibiting pH-independent binding within the physiological range. mā S. H. KRAWCZYK, John F. Milligan, Shalini Wadwani, Courtney Moulds, Brian C. Froehler, Mark D. Matteucci

    I whakaputaina 1992
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    A cytosine analog that confers enhanced potency to antisense oligonucleotides

    A cytosine analog that confers enhanced potency to antisense oligonucleotides mā W. Michael Flanagan, John J. Wolf, Peter Olson, Debbie Grant, Kuei‐Ying Lin, Richard W. Wagner, Mark D. Matteucci

    I whakaputaina 1999
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.

    A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. mā John G. Lewis, Kun Lin, A Kothavale, W. Michael Flanagan, Mark D. Matteucci, Randolph B. DePrince, Robert A. Mook, R. Wayne Hendren, Richard W. Wagner

    I whakaputaina 1996
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

    Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer mā Jessica D. Sun, Qian Liu, Jingli Wang, Dharmendra Ahluwalia, Damien Ferraro, Yan Wang, Jianxin Duan, W. S. Ammons, John G. Curd, Mark D. Matteucci, Charles P. Hart

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

    TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules mā Qian Liu, Jessica D. Sun, Jingli Wang, Dharmendra Ahluwalia, Amanda F. Baker, Lee D. Cranmer, Damien Ferraro, Yan Wang, Jian-Xin Duan, W. S. Ammons, John G. Curd, Mark D. Matteucci, Charles P. Hart

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

    Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302 mā Fanying Meng, James Evans, Deepthi Bhupathi, Monica Banica, Leslie Lan, Gustavo Lorente, Jianxin Duan, Xiaohong Cai, Alexandra M. Mowday, Christopher P. Guise, Andrej Maroz, Robert F. Anderson, Adam V. Patterson, Gregory C. Stachelek, Peter M. Glazer, Mark D. Matteucci, Charles P. Hart

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers

    An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers mā Michele A. Bonham, Stephen Brown, Ann L. Boyd, P H Brown, David A. Bruckenstein, Jeffery C. Hanvey, Stephen A. Thomson, Adrian Pipe, Fred Hassman, John E. Bisi, Brian C. Froehler, Mark D. Matteucci, Richard W. Wagner, Stewart A. Noble, Lee E. Babiss

    I whakaputaina 1995
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: